[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.

733.P1.58 Clinical Results - Autologous Transplantation: Poster I

Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 4, 2010: 5:30 PM-7:30 PM
Hall A3/A4 (Orange County Convention Center)
The Role of High Dose Chemotherapy and Autologous Stem Cell Transplantation In Patients with Multiple Myeloma Refractory to Initial Induction Therapy

Christopher Parrish, MA, MB, BChir, MRCP1*, Amin Rahemtulla, MBBS, PhD, FRCP2, James Cavet, PhD, FRCP, FRCPath3*, Rachel M Pearce4*, Kirkland Keiran, MSc, SRN4*, Julia Lee4*, Charles Craddock5*, Keith Wilson6* and Gordon Cook1

1St James's Institute of Oncology, St James's University Hospital, Leeds, United Kingdom
2Dept. of Hematology, Hammersmith Hospital, London, United Kingdom
3Dept. Haematology, The Christie NHS Foundation Trust, Manchester, United Kingdom
4British Society of Blood and Marrow Transplantation Data Registry, London, United Kingdom
5Centre for Climical Haematology, Dept of Haematology, University of Birmingham and Queen Elizabeth Hospital, Birmingham, United Kingdom
6Department of Haematology, University Hospital of Wales, Cardiff, Wales

Poster Board Number: I-321
Prognostic Index for Predicting Overall Survival and Event-Free Survival In Total Therapy 3 Patients

Antje Hoering, PhD1*, Alan Mitchell1*, Rachael Sexton1*, John Crowley, PhD1 and Bart Barlogie, MD, PhD2

1Research and Biostatistics, Cancer Research and Biostatistics, Seattle, WA
2Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR

Poster Board Number: I-322
Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study

Joyce Habib, MD1*, Neil Dunavin, MD1*, Gary Phillips, MAS2*, Patrick Elder, MS2*, Meaghan Tranovich3*, Don M Benson Jr., MD4, Craig C. Hofmeister, MD5, John C. Byrd, MD3, Steven M. Devine, MD6 and Yvonne Efebera, MD7

1Internal Medicine, The Ohio State University, Columbus, OH
2Center for Biostatistics, The Ohio State University Comprehensive Cancer Center, Columbus, OH
3The Ohio State University, Columbus, OH
4The Ohio State University Medical Center, Columbus, OH
5Internal Medicine, Division of Hematology, The Ohio State University Medical Center, Columbus, OH
6The Ohio State University Comprehensive Cancer Center, Columbus, OH
7The Ohio State University Medical Center

Poster Board Number: I-323
Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone In Patients with AL (Primary) Amyloidosis: Long Term Follow-up of the French Multicentric Randomized Trial

Arnaud Jaccard1*, Veronique Leblond2*, Bruno Royer3*, Xavier Leleu, MD4, Richard Delarue5*, Brigitte Kolb, MD6*, Eric Deconinck7*, Aspasia Stamatoullas8*, Paul Coppo9*, Bertrand Arnulf, MD, PhD10*, Olivier Hermine5*, Philippe Moreau11* and Jean Paul Fermand12*

1CHU, Limoges, France
2Hôpital Pitié-Salpêtrière, Paris, France
3Groupe Francophone des Myelodysplasies, Amiens, France
4Hopital Huriez, CHRU, Lille, France
5Hôpital Necker, Paris, France
6Hôpital Robert Debré, CHU, France
7CHU, Besançon, France
8Centre Becquerel, Rouen, France
9National Reference Center for Thrombotic Microangiopathies, Hôpital Saint Antoine, Paris, France
10Hôpital Saint Louis, APHP, Paris, France
11CHU, Nantes, France
12Hôpital Saint Louis, Paris, France

Poster Board Number: I-324
Multiple Myeloma Patients Who Are Chemosensitive and Present with Plasma Cells Lacking  Phosphorylated Retinoblastoma and/or  Cyclin A  Expression Benefit From High Dose Therapy and Autologous Stem Cell Transplantation More

Selami Kocak Toprak, MD1*, Gulsah Kaygusuz, MD2*, Nazmiye Kursun3*, Duygu Ozu1*, Merih Kizil Cakar, MD1*, Isinsu Kuzu, MD2* and Meral Beksac, MD1

1Department of Hematology, Ankara University School of Medicine, Ankara, Turkey
2Department of Pathology, Ankara University School of Medicine, Ankara, Turkey
3Department of Biostatistics, Ankara University School of Medicine, Ankara, Turkey

Poster Board Number: I-325
Population-Based Study of the Outcomes of Primary Central Nervous System Lymphoma (PCNSL) In the Era of Autologous Stem Cell Transplantation (ASCT)

Carolyn J Owen, MD, FRCPC1, Andrew Daly, MD, FRCPC2, Neil Chua, MD, FRCPC3* and Douglas A. Stewart, MD, FRCP4*

1Division of Hematology, University of Calgary, Southern Alberta Cancer Research Institute, Calgary, AB, Canada
2Peter Lougheed Center, Calgary, AB, Canada
3Cross Cancer Institute, Edmonton, AB, Canada
4Division of Hematology, University of Calgary, Calgary, AB, Canada

Poster Board Number: I-326
Response to Induction Chemotherapy with Novel Agents Does Not Predict Outcomes of Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Salman Osman, MD1*, Abraham Sebastian Kanate, MD2, Pamela Bunner, BS3*, Sonia Leadmon, BS3*, William Tse2, Aaron Cumpston, PharmD4*, Laura Gibson, PhD5*, Scot Remick, MD, FACP1*, Jame Abraham, MD, FACP2*, Michael Craig, MD6 and Sayed Mehdi Hamadani, MD7

1Section of Hematology/Oncology, Dept. of Medicine, West Virginia University, Morgantown, WV
2Section of Hematology and Oncology; Dept. of Medicine, West Virginia University, Morgantown, WV
3Section of Hematology/Oncology, West Virginia University, Morgantown, WV
4Dept. of Pharmacy, West Virginia University, Morgantown
5Professor of Microbiology, Immunology and Cell Biology, Deputy Director, West Virginia University, Morgantown, WV
6Mary Babb Randolph Cancer Center, West Virginia University Robert C Byrd Health Science Center, Morgantown, WV
7Dept. of Medicine Hem./Onc., West Virginia University, Morgantown, WV

Poster Board Number: I-327
The Introduction of Novel Agents Improves Outcomes of Young Patients with Myeloma (MM) Treated with Autologous Stem Cell Transplant (ASCT)

Radovan Saso, MD, MPhil, PhD1*, Kevin D Boyd, MD2*, Kabir Mohammed1*, Ping Wu3*, Jennifer Treleaven1*, Faith E. Davies, MD3 and Gareth J Morgan, MD PhD2

1Dept. of Haematology, The Royal Marsden Hospital, Sutton, England
2Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom
3Section of Haemato-Oncology, The Institute of Cancer Research, London, United Kingdom

Poster Board Number: I-328
Effect of Pharmacokinetic Variability on the Toxicity and Efficacy of High-Dose Melphalan for Multiple Myeloma

Dan T. Vogl, MD, MSCE1, Eric Stoopler, DMD2*, Lisa Davis, PharmD3*, Thomas M. Paul4*, German Salazar, DDS2*, Maria Raguza-Lopez4*, David L. Porter, MD1, Selina M. Luger, MD4* and Edward A. Stadtmauer, MD4*

1Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
2Department of Oral Medicine, University of Pennsylvania School of Dental Medicine, Philadelphia, PA
3Department of Pharmaceutical Sciences, University of the Sciences in Philadelphia, Philadelphia, PA
4Myeloma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

Poster Board Number: I-329
High Dose Melphalan with Autologous Stem Cell Transplantation Overcomes Poor Prognosis of Primary Amyloidosis

Simrit Parmar, M.D.1, Mubeen Khan1*, Gabriela Rondon, MD1*, Nina Shah, MD1*, Qaiser Bashir, MD2*, Shawndeep Tung, MD1*, Jatin J Shah, MD3, Donna Weber, MD3, Robert Z. Orlowski, MD, PhD3, Sergio Giralt, MD4, Richard E. Champlin, MD1 and Muzaffar H. Qazilbash, MD1

1Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
3Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
4Allogeneic Bone Marrow Transplant Service-Medicine , Memorial Sloan-Kettering Cancer Center, New York, NY

Poster Board Number: I-330
Impact of Response to Thalidomide, Lenalidomide or Bortezomib Containing Induction Chemotherapy on Outcomes of Multiple Myeloma Patients Undergoing Autologous Transplantation – A Multicenter Analysis

Farrukh Awan, MD, MS1, Salman Osman, MD2*, Samith Thomas Kochuparambil3*, Scot Remick, MD, FACP4*, Jame Abraham, MD, FACP5*, Michael Craig, MD6, Anand P. Jillella, MD3 and Sayed Mehdi Hamadani, MD7

1Hematology/Oncology, Georgia Health Sciences University, Augusta, GA
2Section of Hematology/Oncology, Dept. of Medicine, West Virginia University, Morgantown
3Medical College of Georgia, Augusta, GA
4Section of Hematology/Oncology, Dept. of Medicine, West Virginia University, Morgantown, WV
5Section of Hematology and Oncology; Dept. of Medicine, West Virginia University, Morgantown, WV
6Mary Babb Randolph Cancer Center, West Virginia University Robert C Byrd Health Science Center, Morgantown, WV
7Dept. of Medicine Hem./Onc., West Virginia University, Morgantown, WV

Poster Board Number: I-331
Autotransplants for Multiple Myeloma (MM) – An Update of the Arkansas Experience Since 1989 In Almost 4000 Patients with Special Emphasis on Third and Further Transplants

Bijay Nair, MD, MPH1, Elias J. Anaissie, MD1, Sarah Waheed, MD1*, Yazan Alsayed, MD1*, Rachael Sexton2*, Nathan Petty1*, Frits van Rhee, MD, PhD1, Antje Hoering, PhD2* and Bart Barlogie, MD, PhD1

1Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
2Research and Biostatistics, Cancer Research and Biostatistics, Seattle, WA

Poster Board Number: I-332
Outcomes Following Salvage Autologous Stem Cell Transplant for Multiple Myeloma

Daniel E Fein1*, Hani Hassoun, MD1, Raymond L. Comenzo, MD2, Alex Lesokhin, MD3*, Nikoletta Lendvai, MD PhD3*, David Chung, MD PhD4, Adam Cohen5*, Michael A. Rosenzweig, MD1*, Danielle Chimento, BA6*, Xiaoyu Jia1*, Stephen Nimer1*, Sergio Giralt, MD1 and Heather Landau, MD1

1Memorial Sloan-Kettering Cancer Center, New York, NY
2Tufts Medical Center, Boston, MA
3Myeloma/Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY
4Adult BMT service, Memorial Sloan-Kettering Cancer Center, New York, NY
5Fox Chase Cancer Center, Philadelphia, PA
6Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

Poster Board Number: I-333
Analysis of Serial Body Height Measurements In Total Therapy 2 (TT2, Control v Thalidomide Arm) and Total Therapy 3 (A: VTD Maintenance; B: VRD Maintenance) as a Guide to Overall Bone Health In Multiple Myeloma (MM)

Alan Mitchell1*, Antje Hoering, PhD1*, Frits van Rhee, MD, PhD2, Elias J. Anaissie, MD2, John Crowley, PhD1 and Bart Barlogie, MD, PhD2

1Research and Biostatistics, Cancer Research and Biostatistics, Seattle, WA
2Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR

Poster Board Number: I-334
High Dose Intravenous Busulfan (BU) and Melphalan (MEL ) Followed by Bortezomib (BTZ) as Conditioning with Autologous Peripheral Blood Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (MM)

Tulio E. Rodriguez, MD1*, Patrick J. Stiff, MD1, Scott E. Smith, MD, PhD, FACP1*, Jonathan L. Kaufman, MD2, Mary Lee, RN1*, Mala Parthasarathy, MS1*, Zachary M. Earley3*, Sagar Lonial, MD2 and David H. Vesole, MD, PhD4

1Cardinal Bernardin Cancer Center, Loyola University Chicago Medical Center, Maywood, IL
2Hematology and Medical Oncology, Emory University, Winship Cancer Institute, Atlanta, GA
3Loyola University Chicago, Chicago
4The John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ

Poster Board Number: I-335
Total Therapy 2 (TT2) for Multiple Myeloma (MM): Contributions to Survival Outcomes of Dosing of Thalidomide (T), Dexamethasone (D) and Interferon (I) Maintenance Components

Frits van Rhee, MD, PhD1, Bart Barlogie, MD, PhD1, Jackie Szymonifka2*, Elias J. Anaissie, MD1, Bijay Nair, MD1, Sarah Waheed, MD1*, Yazan Alsayed, MD1*, Nathan M Petty1*, John D Shaughnessy Jr., PhD1, Antje Hoering, PhD2* and John Crowley, PhD2

1Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
2Research and Biostatistics, Cancer Research and Biostatistics, Seattle, WA

Poster Board Number: I-336
The Addition of Rituximab and/or Alpha-Interferon to High Dose Chemotherapy and Autologous Stem Cell Transplantation for Patients with Relapsed Follicular Lymphoma Produces Durable Progression Free Survival and Molecular Remissions

Sita Bhella, MD1*, Neil L Berinstein, MD, FRCPC2*, Nancy Pennell, BSc3*, Matthew Cheung, MD, FRCPC3, Kevin R. Imrie, MD, FRCPC3, Violet Miliken3*, Marciano D. Reis, MD, FRCPC3, Alden Chesney, MD, FRCPC3*, David Good, MD, FRCPC3, Lisa Hicks, MD, MSc, FRCPC4, Eugenia Piliotis, MD, FRCPC3, Michael Crump, MD, FRCPC5* and Rena Buckstein, MD, FRCPC3*

1General Internal Medicine, University of Toronto, Toronto, ON, Canada
2Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
3Sunnybrook Health Sciences Centre, Odette Cancer Centre, Toronto, ON, Canada
4St. Michael's Hospital, Toronto, ON, Canada
5Princess Margaret Hospital, University Health Network, Toronto, ON, Canada

Poster Board Number: I-337
High-Dose Therapy (HDT) with Hematopoietic Stem Cell Transplantation (HSCT) Is Effective Therapy for Patients with Non-Hodgkin Lymphoma (NHL) and Central Nervous System (CNS) Involvement

R. Gregory Bociek, MD1, Peerapon Wong, MD2*, Fausto R. Loberiza Jr., MD, MS3*, Philip Bierman, MD4, Julie M. Vose4, Nicole Shonka, MD4* and James O. Armitage, MD4

1Division of Oncology/Hematology, University of Nebraska Medical Center, Omaha, NE
2Faculty of Medicine, Naresuan University, Phitsanulok, Thailand
3Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE
4Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Poster Board Number: I-338
Pharmocokinetic (PK)-Directed High Dose Intravenous Busulfan, Cyclophosphamide and Etoposide Produces Predictable Drug Exposure and Durable Long Term Survival In Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

Hongzheng Zhang, MPH PhD1*, Michael Graiser1*, Donald Hutcherson1*, M. Olufemi Dada1*, Stephanie McMillan, BSN, RN, OCN1*, Ali Zahir1*, Christopher R Flowers, MD, MS1 and Edmund K Waller, MD PhD2

1Hematology and Medical Oncology, Winship Cancer Institute, Emory School of Medicine, Atlanta, GA
2Department of Heamtology/Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA

Poster Board Number: I-339

*signifies non-member of ASH